Search results for "Cost Control"

showing 3 items of 3 documents

Percutaneous liver biopsy: a safe outpatient procedure?

2001

Following the discovery of hepatitis C virus, more liver biopsies (LB) than before are being performed to assess the severity of liver disease. In this study, following the recommendations for outpatient LB made by the Patient Care Committee of the American Gastroenterological Association, we assessed the feasibility and benefits of LB performed as an outpatient versus inpatient procedure over the last 7 years in our centre. The study included 1,581 patients consecutively examined in our institute; all LBs were performed by a single operator with a 16-gauge needle using the Menghini technique, and in all cases the puncture site was determined using prebiopsy ultrasound. Liver lesions were c…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCost ControlChronic liver diseaseLiver biopsy complicationLiver diseasePatient satisfactionAmbulatory careBiopsyAmbulatory CareMedicineHumansAgedRetrospective StudiesUltrasonographymedicine.diagnostic_testbusiness.industryPatient SelectionChronic liver diseaseBiopsy NeedleHaemobiliaGastroenterologyOutpatientRetrospective cohort studyHealth Care CostsMiddle Agedmedicine.diseaseSurgeryLiverPatient SatisfactionFemalebusinessComplicationDigestion
researchProduct

Suitability of the ASA Model in Nigeria

2010

This paper looks at the lending methodology adopted by ASA International in Nigeria and how the model is suited for operations within the Nigerian microfinance sector. It begins by examining the critical success factors that contribute towards ASA having a lean operations, how it manages operations efficiencies, and finally makes a set of recommendations that Nigerian Microfinance Institutions could adopt.

Cost reductionMicrofinanceEngineeringlawbusiness.industryCritical success factorCost controlOperations managementbusinessLean manufacturingIndustrial organizationlaw.inventionSSRN Electronic Journal
researchProduct

Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale

2002

Abstract Introduction: Platinum-based chemotherapy is the gold standard in advanced non-small cell lung cancer (NSCLC), although with relevant toxic effects. Both docetaxel (DCT) and gemcitabine (GEM) have shown activity as single agent in advanced NSCLC with a different toxicity profile and a lack of cross-resistance. Materials and methods: From April 2000 to May 2001, 47 consecutive patients were enrolled in a multicenter phase II trial. Main inclusion criteria included untreated patients with histologically confirmed NSCLC, age⩽70 years, stage IIIB/IV, Eastern Cooperative Oncology Group performance status (PS) 0–2, measurable disease, adequate hematologic, cardiac, hepatic and renal func…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaCost ControlPaclitaxelSurvivalmedicine.medical_treatmentPhases of clinical researchDocetaxelNeutropeniaDeoxycytidineGastroenterologyDrug CostsCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansLung cancerAgedChemotherapybusiness.industryMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryTreatment OutcomeOncologyDocetaxelDisease ProgressionFemaleTaxoidsbusinessProgressive diseasemedicine.drugLung Cancer
researchProduct